Mary Sams, MD
Internal Medicine · Atlanta, GANPI 1053443275
Payments from drug & device makers
Across 337 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$747
- Lilly USA, LLC$544
- Pfizer$337
- Novo Nordisk$334
- UCB, Inc.$303
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,353100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 127 | $2,328 |
| AbbVie | 40 | $747 |
| Lilly USA, LLC | 31 | $544 |
| Pfizer | 19 | $337 |
| Novo Nordisk | 19 | $334 |
| UCB, Inc. | 16 | $303 |
| Johnson & Johnson | 16 | $284 |
| Mallinckrodt Hospital Products Inc. | 8 | $211 |
| Esperion Therapeutics, Inc. | 8 | $141 |
| Bristol Myers Squibb | 6 | $124 |
| Madrigal Pharmaceuticals | 1 | $108 |
| Astellas Pharma US Inc | 5 | $96 |
| AstraZeneca | 4 | $92 |
| Exact Sciences | 4 | $81 |
| ANI Pharmaceuticals, Inc. | 3 | $81 |
| GSK | 5 | $79 |
| Radius Health, Inc. | 5 | $77 |
| Dynavax Technologies Corporation | 2 | $47 |
| Mallinckrodt Enterprises LLC | 2 | $39 |
| Sobi, Inc | 2 | $32 |
| Hikma Pharmaceuticals USA | 1 | $26 |
| Novartis | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Bayer | 1 | $23 |
| IBSA Pharma Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Inari Medical, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Linus Health, Inc. | 1 | $15 |
| Vyaire Medical, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$108
How this compares
$6,353 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 77 | $100,316 |
| MounjaroTirzepatide | 72 | $84,633 |
| OzempicSemaglutide | 48 | $57,438 |
| FarxigaDapagliflozin Propanediol | 34 | $43,000 |
| CreonLipase/Protease/Amylase | 20 | $35,132 |
| RybelsusSemaglutide | 14 | $23,722 |
| SynthroidLevothyroxine Sodium | 186 | $20,268 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $11,091 |
| PremarinEstrogens, Conjugated | 18 | $8,739 |
| Ezetimibe | 267 | $8,518 |
| Atorvastatin Calcium | 682 | $6,378 |
| Levothyroxine Sodium | 565 | $5,517 |
| Rosuvastatin Calcium | 458 | $5,418 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,880 |
| Lisdexamfetamine Dimesylate | 18 | $4,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $337 | $109,05595 claims |
| Lilly USA, LLCMounjaro | $544 | $84,63372 claims |
| Novo NordiskOzempic, Rybelsus | $334 | $81,16062 claims |
| AbbVieCreon, Synthroid | $747 | $55,400206 claims |
| AstraZenecaFarxiga, Symbicort | $92 | $47,88053 claims |
| GSKTrelegy Ellipta | $79 | $11,09112 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $81 | $1,84344 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Atlanta
- Kimball JohnsonAtlanta$51.1M
- Robert Springer IiiAtlanta$5.3M
- Paulina Rebolledo EsteinouAtlanta$2.1M
- Courtney SheltonAtlanta$1.2M
- Melanie ThompsonAtlanta$1.1M
- Tracey HenryAtlanta$305K
- David WatsonAtlanta$286K
- Priscilla Igho-PemuAtlanta$269K
- Robert HerreraAtlanta$261K
- Syed RahmanAtlanta$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.